Open-angle glaucoma: Tips for earlier detection and treatment selection

Journal of Family Practice

Volumn 54, Issue 2, 2005, Pages 117-125

  Aref, Ahmad A ^a,b   Schmitt, Brian P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VA Chicago Health Care System ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; BUNOLOL; CARBACHOL; CARTEOLOL; DORZOLAMIDE; LATANOPROST; METIPRANOLOL; PILOCARPINE; TIMOLOL; TRAVOPROST;

ALLERGY; ARTHRALGIA; BRADYCARDIA; BRONCHOSPASM; CATARACT; CONJUNCTIVITIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRY NOSE; EYELASH; HEADACHE; HISTORY OF MEDICINE; HUMAN; HYPOTENSION; INTRAOCULAR PRESSURE; LASER SURGERY; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; MYALGIA; MYOPIA; OPEN ANGLE GLAUCOMA; PRIMARY MEDICAL CARE; REVIEW; RISK FACTOR; TRABECULECTOMY; VISION; XEROSTOMIA;

AGE FACTORS; EARLY DIAGNOSIS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMOSCOPY; PATIENT CARE PLANNING; PROGNOSIS; RISK FACTORS; VISUAL FIELDS;

EID: 13444271872     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Zeyen TG, Caprioli J. Progression of disc and field damage in early glaucoma. Arch Ophthalmol 1993; 111:62-65.
2. American Academy of Ophthalmology, Glaucoma Panel. Primary open-angle glaucoma, Limited Revision. Preferred practice pattern. San Francisco: American Academy of Ophthalmology, 2003:1-37.
3. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991; 266:369-374.
4. Quigley HA, Vitale S. Models of glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38:83-91.
5. Schappert SM. Office visits for glaucoma: United States, 1991-92. Adv Data 1995; 262:1-14.
6. th ed. Philadelphia, Pa: W.B. Saunders Company, 1999:1374-1375.
7. Congdon N, Wang F, Tielsch JM. Issues in epidemiology and population-based screening of primary angle-closure glaucoma. Surv Ophthalmol 1992; 36:411-423.
8. Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol 1998; 116:1640-1645.
9. Quigley HA. Open-angle glaucoma. N Eng J Med 1993; 328:1097-1106.
10. Harper R, Reeves B. The sensitivity and specificity of direct ophthalmoscopic optic disc assessment in screening for glaucoma: a multivariate analysis. Graefes Arch Clin Exp Ophthalmol 2000; 238:949-955.
11. nd ed. St. Louis, Mo: Mosby-Yearbook, 1996:411.
12. Lichter PR. Variability of expert observers in evaluating the optic disc. Trans Am Ophthalmol Soc 1976; 74:532-572.
13. Smith OU, Seligsohn AL, Khan SJ, Spaeth GL. Primary Open Angle Glaucoma. American College of Physicians PIER Guideline. 2004.
14. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: The Baltimore Eye Survey. Am J Epidemiol 1991; 134:1102-1110.
15. Katz J, Sommer A, Gaasterland DE, Anderson DR. Comparison of analytic algorithms for detecting glaucomatous visual field loss. Arch Ophthalmol 1991; 109:1684-1689.
16. Colton T, Ederer F. The distribution of intraocular pressures in the general population. Surv Ophthalmol 1980; 25:123.
17. Brandt JD, Beiser JA, Kass MA et al. Central corneal thickness in the Ocular Hypertension Treatment Study. Opthalmology 2001; 108:1779-1788.
18. Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Opthalmol 2004; 122:17-21.
19. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992; 99:1499-1504.
20. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Study. Ophthalmology 1996; 103:1661-1669.
21. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. The Cochrane Library, Volume 1, 2004.
22. Quigley HA. Identification of glaucoma-related visual field abnormality with the screening protocol of frequency doubling technology. Am J Ophthalmol 1998; 125:819-829.
23. The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS). The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:4:429-440.
24. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126:4:487-497.
25. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Kornakoff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Early Manifest Glaucoma Trial Group. Arch Ophthalmol 2003; 121:48-56.
26. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124:544-547.
27. Alward WL. Medical management of glaucoma. N Eng J Med 1998; 339:1298-1307.
28. Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol 1990; 108:1264-1267.
29. Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol 1995; 113:293-296.
30. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 2% brimonidine. Arch Ophthalmol 1995; 113:77-83.
31. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991; 98:308-312.
32. Hyong PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000; 59:411-434.
33. Avorn J, Glynn RJ, Gurwitz JH, et al. Adverse pulmonary effects of topical beta blockers used in the treatment of glaucoma. J Glaucoma 1993; 2:158-165.
34. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986; 104:197-199.
35. Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986. Am J Ophthalmol 1987; 103:512.
36. Yogel R, Tipping R, Kudaga SF, Clineschmidt CM. Timolol-Betaxolol Study Group. Changing therapy from timolol to betaxolol: effect on intraocular pressure in selected patients with glaucoma. Arch Ophthalmol 1989; 107:1303-1307.
37. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM; Bimatoprost Circadian IOP Study Group. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004; 49 Suppl 1:S26-S35.
38. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120:1286-1293.
39. Schadlu R, Maus TL, Nau CB, Brubaker RE. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol 1998; 116:1441-1444.
40. th ed. New York, NY: Lange Medical Books/McGraw Hill, 2001:102-103.
41. Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol 1998; 116:1433-1437.
42. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol 1995; 120:718-731.
43. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology 1998; 105:146-164.
44. Roth SM, Spaeth GL, Starita RJ, et al. The effects of postoperative corticosteroids on trabeculolectomy and the clinical course of glaucoma: five-year follow-up study. Ophthalmic Surg 1991; 22:924-929.
45. Hylton C, Congdon N, Friedman D, et al. Cataract after glaucoma filtration surgery. Am J Ophthalmol 2003; 135:231-232.
46. Lichter PR, Musch DC, Gillespie BW, et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108:1943-1953.
47. th ed. San Francisco, Calif: American Academy of Ophthalmology, 1999.
48. Gieser JP. When treatment fails, caring for patients with visual disability. Arch Ophthalmol 2004; 122:1208-1209.